Plasminogen Activators in Ischemic Stroke

Matrix Proteases in Health and Disease

Volumn , Issue , 2012, Pages 127-156

  Schielke, Gerald ^a   Lawrence, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

blood brain barrier and PDGFcc; cerebral blood flow; excitotoxicity; ischemic penumbra; ischemic stroke; plasminogen activator; thrombolysis

Indexed keywords

EID: 84885692412     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527649327.ch6     Document Type: Chapter

References (180)

1. Astrup, J., Siesjo, B.K., and Symon, L. (1981) Thresholds in cerebral ischemia - the ischemic penumbra. Stroke, 12 (6), 723-725.
2. Bell, B.A., Symon, L., and Branston, N.M. (1985) CBF and time thresholds for the formation of ischemic cerebral edema, and effect of reperfusion in baboons. J. Neurosurg., 62 (1), 31-41.
3. Strong, A.J., Venables, G.S., and Gibson, G. (1983) The cortical ischaemic penumbra associated with occlusion of the middle cerebral artery in the cat: 1. Topography of changes in blood flow, potassium ion activity, and EEG. J. Cereb. Blood Flow Metab., 3 (1), 86-96.
4. Benveniste, H., Drejer, J., Schousboe, A., and Diemer, N.H. (1984) Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem., 43 (5), 1369-1374.
5. Shin, H.K., Dunn, A.K., Jones, P.B., Boas, D.A., Moskowitz, M.A., and Ayata, C. (2006) Vasoconstrictive neurovascular coupling during focal ischemic depolarizations. J. Cereb. Blood Flow Metab., 26 (8), 1018-1030.
6. Back, T., Ginsberg, M.D., Dietrich, W.D., and Watson, B.D. (1996) Induction of spreading depression in the ischemic hemisphere following experimental middle cerebral artery occlusion: effect on infarct morphology. J. Cereb. Blood Flow Metab., 16 (2), 202-213.
7. Betz, A.L. (1996) Alterations in cerebral endothelial cell function in ischemia. Adv. Neurol., 71, 301-311; discussion 311-313.
8. Barone, F.C. and Feuerstein, G.Z. (1999) Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow Metab., 19 (8), 819-834.
9. Ginsberg, M.D. and Pulsinelli, W.A. (1994) The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke. Ann. Neurol., 36 (4), 553-554.
10. Jones, T.H., Morawetz, R.B., Crowell, R.M., Marcoux, F.W., FitzGibbon, S.J., DeGirolami, U., and Ojemann, R.G. (1981) Thresholds of focal cerebral ischemia in awake monkeys. J. Neurosurg., 54 (6), 773-782.
11. Overgaard, K., Sereghy, T., Pedersen, H., and Boysen, G. (1994) Effect of delayed thrombolysis with rt-PA in a rat embolic stroke model. J. Cereb. Blood Flow Metab., 14 (3), 472-477.
12. Kaplan, B., Brint, S., Tanabe, J., Jacewicz, M., Wang, X.J., and Pulsinelli, W. (1991) Temporal thresholds for neocortical infarction in rats subjected to reversible focal cerebral ischemia. Stroke, 22 (8), 1032-1039.
13. Memezawa, H., Smith, M.L., and Siesjo, B.K. (1992) Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats. Stroke, 23 (4), 552-559.
14. Hanaway, J., Torack, R., Fletcher, A.P., and Landau, W.M. (1976) Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke. Stroke, 7 (2), 143-146.
15. Lyden, P.D., Madden, K.P., Clark, W.M., Sasse, K.C., and Zivin, J.A. (1990) Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke, 21 (11), 1589-1593.
16. Zivin, J.A., Fisher, M., DeGirolami, U., Hemenway, C.C., and Stashak, J.A. (1985) Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science, 230, 1289-1292.
17. NINDA and Stroke rtPA Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-PA stroke study group. N. Engl. J. Med., 333 (24), 1581-1587.
18. NINDA and Stroke rtPA Study Group (1997) Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke, 28 (11), 2109-2118.
19. Hacke, W., Kaste, M., Fieschi, C., Toni, D., Lesaffre, E., von Kummer, R., Boysen, G., Bluhmki, E., Hoxter, G., Mahagne, M.H. et al. (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA, 274 (13), 1017-1025.
20. Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., Schneider, D., Diez-Tejedor, E., and Trouillas, P. (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet, 352 (9136), 1245-1251.
21. Clark, W.M., Wissman, S., Albers, G.W., Jhamandas, J.H., Madden, K.P., and Hamilton, S. (1999) Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. J. Am. Med. Assoc., 282 (21), 2019-2026.
22. Hacke, W., Donnan, G., Fieschi, C., Kaste, M., von Kummer, R., Broderick, J.P., Brott, T., Frankel, M., Grotta, J.C., Haley, E.C. Jr., Kwiatkowski, T., Levine, S.R., Lewandowski, C., Lu, M., Lyden, P., Marler, J.R., Patel, S., Tilley, B.C., Albers, G., Bluhmki, E., Wilhelm, M., and Hamilton, S. (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, 363 (9411), 768-774.
23. Cronin, C.A. (2010) Intravenous tissue plasminogen activator for stroke: a review of the ECASS III results in relation to prior clinical trials. J. Emerg. Med., 38 (1), 99-105.
24. Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Davalos, A., Guidetti, D., Larrue, V., Lees, K.R., Medeghri, Z., Machnig, T., Schneider, D., von Kummer, R., Wahlgren, N., and Toni, D. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med., 359 (13), 1317-1329.
25. Saver, J.L., Gornbein, J., Grotta, J., Liebeskind, D., Lutsep, H., Schwamm, L., Scott, P., and Starkman, S. (2009) Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial. Stroke, 40 (7), 2433-2437.
26. Del Zoppo, G.J., Saver, J.L., Jauch, E.C., and Adams, H.P. Jr. (2009) Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American heart association/American stroke association. Stroke, 40 (8), 2945-2948.
27. Donnan, G.A., Baron, J.C., Ma, H., and Davis, S.M. (2009) Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol., 8 (3), 261-269.
28. Baron, J.C. (1999) Mapping the ischaemic penumbra with PET: implications for acute stroke treatment. Cerebrovasc. Dis., 9 (4), 193-201.
29. Heiss, W.D., Kracht, L.W., Thiel, A., Grond, M., and Pawlik, G. (2001) Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain, 124 (Pt 1), 20-29.
30. Heiss, W.D., Sobesky, J., Smekal, U., Kracht, L.W., Lehnhardt, F.G., Thiel, A., Jacobs, A.H., and Lackner, K. (2004) Probability of cortical infarction predicted by flumazenil binding and diffusion-weighted imaging signal intensity: a comparative positron emission tomography/magnetic resonance imaging study in early ischemic stroke. Stroke, 35 (8), 1892-1898.
31. Parsons, M.W., Christensen, S., McElduff, P., Levi, C.R., Butcher, K.S., De Silva, D.A., Ebinger, M., Barber, P.A., Bladin, C., Donnan, G.A., and Davis, S.M. (2010) Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J. Cereb. Blood Flow Metab., 30 (6), 1214-1225.
32. Albers, G.W., Thijs, V.N., Wechsler, L., Kemp, S., Schlaug, G., Skalabrin, E., Bammer, R., Kakuda, W., Lansberg, M.G., Shuaib, A., Coplin, W., Hamilton, S., Moseley, M., and Marks, M.P. (2006) Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann. Neurol., 60 (5), 508-517.
33. Davis, S.M., Donnan, G.A., Parsons, M.W., Levi, C., Butcher, K.S., Peeters, A., Barber, P.A., Bladin, C., De Silva, D.A., Byrnes, G., Chalk, J.B., Fink, J.N., Kimber, T.E., Schultz, D., Hand, P.J., Frayne, J., Hankey, G., Muir, K., Gerraty, R., Tress, B.M., and Desmond, P.M. (2008) Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol., 7 (4), 299-309.
34. Nagakane, Y., Christensen, S., Brekenfeld, C., Ma, H., Churilov, L., Parsons, M.W., Levi, C.R., Butcher, K.S., Peeters, A., Barber, P.A., Bladin, C.F., De Silva, D.A., Fink, J., Kimber, T.E., Schultz, D.W., Muir, K.W., Tress, B.M., Desmond, P.M., Davis, S.M., and Donnan, G.A. (2011) EPITHET: positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke, 42 (1), 59-64.
35. Paciaroni, M., Medeiros, E., and Bogousslavsky, J. (2009) Desmoteplase. Expert Opin. Biol. Ther., 9 (6), 773-778.
36. Liberatore, G.T., Samson, A., Bladin, C., Schleuning, W.D., and Medcalf, R.L. (2003) Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke, 34 (2), 537-543.
37. Furlan, A.J., Eyding, D., Albers, G.W., Al-Rawi, Y., Lees, K.R., Rowley, H.A., Sachara, C., Soehngen, M., Warach, S., and Hacke, W. (2006) Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke, 37 (5), 1227-1231.
38. Hacke, W., Albers, G., Al-Rawi, Y., Bogousslavsky, J., Davalos, A., Eliasziw, M., Fischer, M., Furlan, A., Kaste, M., Lees, K.R., Soehngen, M., and Warach, S. (2005) The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke, 36 (1), 66-73.
39. Hacke, W., Furlan, A.J., Al-Rawi, Y., Davalos, A., Fiebach, J.B., Gruber, F., Kaste, M., Lipka, L.J., Pedraza, S., Ringleb, P.A., Rowley, H.A., Schneider, D., Schwamm, L.H., Leal, J.S., Sohngen, M., Teal, P.A., Wilhelm-Ogunbiyi, K., Wintermark, M., and Warach, S. (2009) Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol., 8 (2), 141-150.
40. Molina, C.A. (2010) Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches. Stroke, 42 (Suppl. 1), S16-S19.
41. Mishra, N.K., Albers, G.W., Davis, S.M., Donnan, G.A., Furlan, A.J., Hacke, W., and Lees, K.R. (2010) Mismatch-based delayed thrombolysis: a meta-analysis. Stroke, 41 (1), e25-e33.
42. Ogawa, A., Mori, E., Minematsu, K., Taki, W., Takahashi, A., Nemoto, S., Miyamoto, S., Sasaki, M., and Inoue, T. (2007) Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke, 38 (10), 2633-2639.
43. Del Zoppo, G.J., Copeland, B.R., Waltz, T.A., Zyroff, J., Plow, E.F., and Harker, L.A. (1986) The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke, 17 (4), 638-643.
44. Furlan, A., Higashida, R., Wechsler, L., Gent, M., Rowley, H., Kase, C., Pessin, M., Ahuja, A., Callahan, F., Clark, W.M., Silver, F., and Rivera, F. (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. J. Am. Med. Assoc., 282 (21), 2003-2011.
45. Martin, U., Kaufmann, B., and Neugebauer, G. (1999) Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective. Clin. Pharmacokinet., 36 (4), 265-276.
46. Qureshi, A.I., Siddiqui, A.M., Suri, M.F., Kim, S.H., Ali, Z., Yahia, A.M., Lopes, D.K., Boulos, A.S., Ringer, A.J., Saad, M., Guterman, L.R., and Hopkins, L.N. (2002) Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery, 51 (5), 1319-1327; discussion 1327-1329.
47. Davydov, L. and Cheng, J.W. (2001) Tenecteplase: a review. Clin. Ther., 23 (7), 982-997; discussion 981.
48. Haley, E.C. Jr., Thompson, J.L., Grotta, J.C., Lyden, P.D., Hemmen, T.G., Brown, D.L., Fanale, C., Libman, R., Kwiatkowski, T.G., Llinas, R.H., Levine, S.R., Johnston, K.C., Buchsbaum, R., Levy, G., and Levin, B. (2010) Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke, 41 (4), 707-711.
49. Parsons, M.W., Miteff, F., Bateman, G.A., Spratt, N., Loiselle, A., Attia, J., and Levi, C.R. (2009) Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology, 72 (10), 915-921.
50. Deitcher, S.R., Funk, W.D., Buchanan, J., Liu, S., Levy, M.D., and Toombs, C.F. (2006) Alfimeprase: a novel recombinant direct-acting fibrinolytic. Expert Opin. Biol. Ther., 6 (12), 1361-1369.
51. Killer, M., Ladurner, G., Kunz, A.B., and Kraus, J. (2010) Current endovascular treatment of acute stroke and future aspects. Drug Discov. Today, 15 (15-16), 640-647.
52. Gibson, C.M., Zorkun, C., Molhoek, P., Zmudka, K., Greenberg, M., Mueller, H., Wesdorp, J., Louwerenburg, H., Niederman, A., Westenburg, J., Bikkina, M., Batty, J., de Winter, J., Murphy, S.A., and McCabe, C.H. (2006) Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial. J. Thromb. Thrombolysis, 22 (1), 13-21.
53. Lapchak, P.A., Araujo, D.M., Pakola, S., Song, D., Wei, J., and Zivin, J.A. (2002) Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke, 33 (9), 2279-2284.
54. Thijs, V.N., Peeters, A., Vosko, M., Aichner, F., Schellinger, P.D., Schneider, D., Neumann-Haefelin, T., Rother, J., Davalos, A., Wahlgren, N., and Verhamme, P. (2009) Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke. Stroke, 40 (12), 3789-3795.
55. Collen, D. (1998) Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat. Med., 4 (3), 279-284.
56. Armstead, W.M., Ganguly, K., Kiessling, J.W., Chen, X.H., Smith, D.H., Higazi, A.A., Cines, D.B., Bdeir, K., Zaitsev, S., and Muzykantov, V.R. (2009) Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J. Cereb. Blood Flow Metab., 29 (8), 1463-1474.
57. Ganguly, K., Krasik, T., Medinilla, S., Bdeir, K., Cines, D.B., Muzykantov, V.R., and Murciano, J.C. (2005) Blood clearance and activity of erythrocyte-coupled fibrinolytics. J. Pharmacol. Exp. Ther., 312 (3), 1106-1113.
58. Murciano, J.C. and Muzykantov, V.R. (2003) Coupling of anti-thrombotic agents to red blood cells offers safer and more effective management of thrombosis. Discov. Med., 3 (18), 28-29.
59. Lees, K.R., Bluhmki, E., von Kummer, R., Brott, T.G., Toni, D., Grotta, J.C., Albers, G.W., Kaste, M., Marler, J.R., Hamilton, S.A., Tilley, B.C., Davis, S.M., Donnan, G.A., Hacke, W., Allen, K., Mau, J., Meier, D., Del Zoppo, G., De Silva, D.A., Butcher, K.S., Parsons, M.W., Barber, P.A., Levi, C., Bladin, C., and Byrnes, G. (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 375 (9727), 1695-1703.
60. Dirks, M., Niessen, L.W., van Wijngaarden, J.D., Koudstaal, P.J., Franke, C.L., van Oostenbrugge, R.J., Huijsman, R., Lingsma, H.F., Minkman, M.M., and Dippel, D.W. (2011) Promoting thrombolysis in acute ischemic stroke. Stroke, 42 (5), 1325-1330.
61. Plow, E.F., Herren, T., Redlitz, A., Miles, L.A., and Hoover-Plow, J.L. (1995) The cell biology of the plasminogen system. FASEB J., 9 (10), 939-945.
62. Seeds, N.W., Verrall, S., Friedman, G., Hayden, S., Gadotti, D., Haffke, S., Christensen, K., Gardner, B., McGuire, P., and Krystosek, A. (1992) Plasminogen activators and plasminogen activator inhibitors in neural development. Ann. N.Y. Acad. Sci., 667, 32-40.
63. Ware, J.H., Dibenedetto, A.J., and Pittman, R.N. (1995) Localization of tissue plasminogen activator mRNA in adult rat brain. Brain Res. Bull., 37 (3), 275-281.
64. Ware, J.H., DiBenedetto, A.J., and Pittman, R.N. (1995) Localization of tissue plasminogen activator mRNA in the developing rat cerebellum and effects of inhibiting tissue plasminogen activator on granule cell migration. J. Neurobiol., 28 (1), 9-22.
65. Sappino, A.P., Madani, R., Huarte, J., Belin, D., Kiss, J.Z., Wohlwend, A., and Vassalli, J.D. (1993) Extracellular proteolysis in the adult murine brain. J. Clin. Invest., 92 (2), 679-685.
66. Teesalu, T., Kulla, A., Simisker, A., Siren, V., Lawrence, D.A., Asser, T., and Vaheri, A. (2004) Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb. Haemost., 92 (2), 358-368.
67. Hastings, G.A., Coleman, T.A., Haudenschild, C.C., Stefansson, S., Smith, E.P., Barthlow, R., Cherry, S., Sandkvist, M., and Lawrence, D.A. (1997) Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J. Biol. Chem., 272 (52), 33062-33067.
68. Krueger, S.R., Ghisu, G.P., Cinelli, P., Gschwend, T.P., Osterwalder, T., Wolfer, D.P., and Sonderegger, P. (1997) Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J. Neurosci., 17 (23), 8984-8996.
69. Hultman, K., Blomstrand, F., Nilsson, M., Wilhelmsson, U., Malmgren, K., Pekny, M., Kousted, T., Jern, C., and Tjarnlund-Wolf, A. (2010) Expression of plasminogen activator inhibitor-1 and protease nexin-1 in human astrocytes: Response to injury-related factors. J. Neurosci. Res., 88 (11), 2441-2449.
70. Noel, M., Norris, E.H., and Strickland, S. (2011) Tissue plasminogen activator is required for the development of fetal alcohol syndrome in mice. Proc. Natl. Acad. Sci. U.S.A., 108 (12), 5069-5074.
71. Reinhard, E., Suidan, H.S., Pavlik, A., and Monard, D. (1994) Glia-derived nexin/protease nexin-1 is expressed by a subset of neurons in the rat brain. J. Neurosci. Res., 37 (2), 256-270.
72. Basham, M.E. and Seeds, N.W. (2001) Plasminogen expression in the neonatal and adult mouse brain. J. Neurochem., 77 (1), 318-325.
73. Taniguchi, Y., Inoue, N., Morita, S., Nikaido, Y., Nakashima, T., Nagai, N., Okada, K., Matsuo, O., and Miyata, S. (2011) Localization of plasminogen in mouse hippocampus, cerebral cortex, and hypothalamus. Cell Tissue Res., 343 (2), 303-317.
74. Tsirka, S.E., Rogove, A.D., Bugge, T.H., Degen, J.L., and Strickland, S. (1997) An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J. Neurosci., 17 (2), 543-552.
75. Baranes, D., Lederfein, D., Huang, Y.Y., Chen, M., Bailey, C.H., and Kandel, E.R. (1998) Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron, 21 (4), 813-825.
76. Seeds, N.W., Williams, B.L., and Bickford, P.C. (1995) Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science, 270 (5244), 1992-1994.
77. Pawlak, R., Rao, B.S., Melchor, J.P., Chattarji, S., McEwen, B., and Strickland, S. (2005) Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc. Natl. Acad. Sci. U.S.A., 102 (50), 18201-18206.
78. Matys, T., Pawlak, R., Matys, E., Pavlides, C., McEwen, B.S., and Strickland, S. (2004) Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. Proc. Natl. Acad. Sci. U.S.A., 101 (46), 16345-16350.
79. Pawlak, R., Magarinos, A.M., Melchor, J., McEwen, B., and Strickland, S. (2003) Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat. Neurosci., 6 (2), 168-174.
80. Park, L., Gallo, E.F., Anrather, J., Wang, G., Norris, E.H., Paul, J., Strickland, S., and Iadecola, C. (2008) Key role of tissue plasminogen activator in neurovascular coupling. Proc. Natl. Acad. Sci. U.S.A., 105 (3), 1073-1078.
81. Salles, F.J. and Strickland, S. (2002) Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J. Neurosci., 22 (6), 2125-2134.
82. Yepes, M., Sandkvist, M., Wong, M.K., Coleman, T.A., Smith, E., Cohan, S.L., and Lawrence, D.A. (2000) Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood, 96 (2), 569-576.
83. Hosomi, N., Lucero, J., Heo, J.H., Koziol, J.A., Copeland, B.R., and Del Zoppo, G.J. (2001) Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke, 32 (6), 1341-1348.
84. Qian, Z., Gilbert, M.E., Colicos, M.A., Kandel, E.R., and Kuhl, D. (1993) Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature, 361 (6411), 453-457.
85. Sappino, A.P., Huarte, J., Belin, D., and Vassalli, J.D. (1989) Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J. Cell Biol., 109 (5), 2471-2479.
86. Carmeliet, P., Schoonjans, L., Kieckens, L., Ream, B., Degen, J., Bronson, R., De Vos, R., van den Oord, J.J., Collen, D., and Mulligan, R.C. (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature, 368 (6470), 419-424.
87. Strickland, S. (2001) Tissue plasminogen activator in nervous system function and dysfunction. Thromb. Haemost., 86 (1), 138-143.
88. Pawlak, R. and Strickland, S. (2002) Tissue plasminogen activator and seizures: a clot-buster's secret life. J. Clin. Invest., 109 (12), 1529-1531.
89. Choi, D.W. (1985) Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci. Lett., 58 (3), 293-297.
90. Tsirka, S.E., Gualandris, A., Amaral, D.G., and Strickland, S. (1995) Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature, 377 (6547), 340-344.
91. Tsirka, S.E., Rogove, A.D., and Strickland, S. (1996) Neuronal cell death and tPA. Nature, 384 (6605), 123-124.
92. Tsirka, S.E., Bugge, T.H., Degen, J.L., and Strickland, S. (1997) Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin. Proc. Natl. Acad. Sci. U.S.A., 94 (18), 9779-9781.
93. Lebeurrier, N., Liot, G., Lopez-Atalaya, J.P., Orset, C., Fernandez-Monreal, M., Sonderegger, P., Ali, C., and Vivien, D. (2005) The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol. Cell. Neurosci., 30 (4), 552-558.
94. Hazell, A.S. (2007) Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem. Int., 50 (7-8), 941-953.
95. Mhairi Macrae, I. (1992) New models of focal cerebral ischaemia. Br. J. Clin. Pharmacol., 34 (4), 302-308.
96. Sigmund, C.D. (2000) Viewpoint: are studies in genetically altered mice out of control? Arterioscler. Thromb. Vasc. Biol., 20 (6), 1425-1429.
97. Wang, Y.F., Tsirka, S.E., Strickland, S., Stieg, P.E., Soriano, S.G., and Lipton, S.A. (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med., 4 (2), 228-231.
98. Del Zoppo, G.J. (1998) tPA: a neuron buster, too? Nat. Med., 4 (2), 148-150.
99. Ginsberg, M.D. (1999) On ischemic brain injury in genetically altered mice. Arterioscler. Thromb. Vasc. Biol., 19 (11), 2581-2583.
100. Tabrizi, P., Wang, L., Seeds, N., McComb, J.G., Yamada, S., Griffin, J.H., Carmeliet, P., Weiss, M.H., and Zlokovic, B.V. (1999) Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler. Thromb. Vasc. Biol., 19 (11), 2801-2806.
101. Kudryk, B.J. and Bini, A. (2000) Monoclonal antibody designated T2G1 reacts with human fibrin beta-chain but not with the corresponding chain from mouse fibrin. Arterioscler. Thromb. Vasc. Biol., 20 (7), 1848-1849.
102. Nagai, N., De Mol, M., Lijnen, H.R., Carmeliet, P., and Collen, D. (1999) Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation, 99 (18), 2440-2444.
103. Nagai, N., Suzuki, Y., Van Hoef, B., Lijnen, H.R., and Collen, D. (2005) Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J. Thromb. Haemost., 3 (7), 1379-1384.
104. Cinelli, P., Madani, R., Tsuzuki, N., Vallet, P., Arras, M., Zhao, C.N., Osterwalder, T., Rulicke, T., and Sonderegger, P. (2001) Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol. Cell. Neurosci., 18 (5), 443-457.
105. Kilic, E., Hermann, D.M., and Hossmann, K.A. (1999) Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice. Neuroreport, 10 (1), 107-111.
106. Zhang, R.L., Chopp, M., Zhang, Z.G., and Divine, G. (1998) Early (1 h) administration of tissue plasminogen activator reduces infarct volume without increasing hemorrhagic transformation after focal cerebral embolization in rats. J. Neurol. Sci., 160 (1), 1-8.
107. Overgaard, K. (1994) Thrombolytic therapy in experimental embolic stroke. Cerebrovasc. Brain Metab. Rev., 6 (3), 257-286.
108. Kilic, E., Bahr, M., and Hermann, D.M. (2001) Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke, 32 (11), 2641-2647.
109. Meng, W., Wang, X., Asahi, M., Kano, T., Asahi, K., Ackerman, R.H., and Lo, E.H. (1999) Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab., 19 (12), 1316-1321.
110. Armstead, W.M., Nassar, T., Akkawi, S., Smith, D.H., Chen, X.H., Cines, D.B., and Higazi, A.A. (2006) Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat. Neurosci., 9 (9), 1150-1155.
111. Lee, S.R., Lok, J., Rosell, A., Kim, H.Y., Murata, Y., Atochin, D., Huang, P.L., Wang, X., Ayata, C., Moskowitz, M.A., and Lo, E.H. (2007) Reduction of hippocampal cell death and proteolytic responses in tissue plasminogen activator knockout mice after transient global cerebral ischemia. Neuroscience, 150 (1), 50-57.
112. Echeverry, R., Wu, J., Haile, W.B., Guzman, J., and Yepes, M. (2010) Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus. J. Clin. Invest., 120 (6), 2194-2205.
113. Lau, A. and Tymianski, M. (2010) Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch., 460 (2), 525-542.
114. Rao, V.R. and Finkbeiner, S. (2007) NMDA and AMPA receptors: old channels, new tricks. Trends Neurosci., 30 (6), 284-291.
115. Kohr, G. (2006) NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res., 326 (2), 439-446.
116. Paoletti, P. and Neyton, J. (2007) NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol., 7 (1), 39-47.
117. Nicole, O., Docagne, F., Ali, C., Margaill, I., Carmeliet, P., MacKenzie, E.T., Vivien, D., and Buisson, A. (2001) The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med., 7 (1), 59-64.
118. Baron, A., Montagne, A., Casse, F., Launay, S., Maubert, E., Ali, C., and Vivien, D. (2010) NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity. Cell Death Differ., 17 (5), 860-871.
119. Benchenane, K., Castel, H., Boulouard, M., Bluthe, R., Fernandez-Monreal, M., Roussel, B.D., Lopez-Atalaya, J.P., Butt-Gueulle, S., Agin, V., Maubert, E., Dantzer, R., Touzani, O., Dauphin, F., Vivien, D., and Ali, C. (2007) Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. J. Cell Sci., 120 (Pt 4), 578-585.
120. Liot, G., Benchenane, K., Leveille, F., Lopez-Atalaya, J.P., Fernandez-Monreal, M., Ruocco, A., Mackenzie, E.T., Buisson, A., Ali, C., and Vivien, D. (2004) 2,7-Bis-(4-amidinobenzylidene)- cycloheptan-1-one dihydrochloride, tPA stop, prevents tPA-enhanced excitotoxicity both in vitro and in vivo. J. Cereb. Blood Flow Metab., 24 (10), 1153-1159.
121. Lopez-Atalaya, J.P., Roussel, B.D., Levrat, D., Parcq, J., Nicole, O., Hommet, Y., Benchenane, K., Castel, H., Leprince, J., To Van, D., Bureau, R., Rault, S., Vaudry, H., Petersen, K.U., Santos, J.S., Ali, C., and Vivien, D. (2008) Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J. Cereb. Blood Flow Metab., 28 (6), 1212-1221.
122. Macrez, R., Bezin, L., Le Mauff, B., Ali, C., and Vivien, D. (2010) Functional occurrence of the interaction of tissue plasminogen activator with the NR1 subunit of N-Methyl-D-Aspartate receptors during stroke. Stroke, 41 (12), 2950-2955.
123. Matys, T. and Strickland, S. (2003) Tissue plasminogen activator and NMDA receptor cleavage. Nat. Med., 9 (4), 371-372; author reply 372-373.
124. Norris, E.H. and Strickland, S. (2007) Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc. Natl. Acad. Sci. U.S.A., 104 (33), 13473-13478.
125. Pawlak, R., Melchor, J.P., Matys, T., Skrzypiec, A.E., and Strickland, S. (2005) Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc. Natl. Acad. Sci. U.S.A., 102 (2), 443-448.
126. Samson, A.L. and Medcalf, R.L. (2006) Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron, 50 (5), 673-678.
127. Yuan, H., Vance, K.M., Junge, C.E., Geballe, M.T., Snyder, J.P., Hepler, J.R., Yepes, M., Low, C.M., and Traynelis, S.F. (2009) The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors. J. Biol. Chem., 284 (19), 12862-12873.
128. Kvajo, M., Albrecht, H., Meins, M., Hengst, U., Troncoso, E., Lefort, S., Kiss, J.Z., Petersen, C.C., and Monard, D. (2004) Regulation of brain proteolytic activity is necessary for the in vivo function of NMDA receptors. J. Neurosci., 24 (43), 9734-9743.
129. Fernandez-Monreal, M., Lopez-Atalaya, J.P., Benchenane, K., Cacquevel, M., Dulin, F., Le Caer, J.P., Rossier, J., Jarrige, A.C., Mackenzie, E.T., Colloc'h, N., Ali, C., and Vivien, D. (2004) Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling. J. Biol. Chem., 279 (49), 50850-50856.
130. Fernandez-Monreal, M., Lopez-Atalaya, J.P., Benchenane, K., Leveille, F., Cacquevel, M., Plawinski, L., MacKenzie, E.T., Bu, G., Buisson, A., and Vivien, D. (2004) Is tissue-type plasminogen activator a neuromodulator? Mol. Cell. Neurosci., 25 (4), 594-601.
131. Samson, A.L., Nevin, S.T., Croucher, D., Niego, B., Daniel, P.B., Weiss, T.W., Moreno, E., Monard, D., Lawrence, D.A., and Medcalf, R.L. (2008) Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J. Neurochem., 107 (4), 1091-1101.
132. Bacskai, B.J., Xia, M.Q., Strickland, D.K., Rebeck, G.W., and Hyman, B.T. (2000) The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. Proc. Natl. Acad. Sci. U.S.A., 97 (21), 11551-11556.
133. Eugenin, E.A., King, J.E., Nath, A., Calderon, T.M., Zukin, R.S., Bennett, M.V., and Berman, J.W. (2007) HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc. Natl. Acad. Sci. U.S.A., 104 (9), 3438-3443.
134. Martin, A.M., Kuhlmann, C., Trossbach, S., Jaeger, S., Waldron, E., Roebroek, A., Luhmann, H.J., Laatsch, A., Weggen, S., Lessmann, V., and Pietrzik, C.U. (2008) The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. J. Biol. Chem., 283 (18), 12004-12013.
135. Qiu, Z., Strickland, D.K., Hyman, B.T., and Rebeck, G.W. (2002) alpha 2-Macroglobulin exposure reduces calcium responses to N-methyl-D-aspartate via low density lipoprotein receptor-related protein in cultured hippocampal neurons. J. Biol. Chem., 277 (17), 14458-14466.
136. Zhou, L., Li, F., Xu, H.B., Luo, C.X., Wu, H.Y., Zhu, M.M., Lu, W., Ji, X., Zhou, Q.G., and Zhu, D.Y. (2010) Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat. Med., 16 (12), 1439-1443.
137. Bard, L., Sainlos, M., Bouchet, D., Cousins, S., Mikasova, L., Breillat, C., Stephenson, F.A., Imperiali, B., Choquet, D., and Groc, L. (2010) Dynamic and specific interaction between synaptic NR2-NMDA receptor and PDZ proteins. Proc. Natl. Acad. Sci. U.S.A., 107 (45), 19561-19566.
138. Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., and Begley, D.J. (2010) Structure and function of the blood-brain barrier. Neurobiol. Dis., 37 (1), 13-25.
139. Betz, A.L. (1992) An overview of the multiple functions of the blood-brain barrier. NIDA Res. Monogr., 120, 54-72.
140. Sandoval, K.E. and Witt, K.A. (2008) Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol. Dis., 32 (2), 200-219.
141. Morancho, A., Rosell, A., Garcia-Bonilla, L., and Montaner, J. (2010) Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment? Ann. N.Y. Acad. Sci., 1207, 123-133.
142. Jin, R., Yang, G., and Li, G. (2010) Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol. Dis., 38 (3), 376-385.
143. Rosell, A. and Lo, E.H. (2008) Multiphasic roles for matrix metalloproteinases after stroke. Curr. Opin. Pharmacol., 8 (1), 82-89.
144. Rosenberg, G.A., Navratil, M., Barone, F., and Feuerstein, G. (1996) Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J. Cereb. Blood Flow Metab., 16 (3), 360-366.
145. Suzuki, Y. (2010) Role of tissue-type plasminogen activator in ischemic stroke. J. Pharmacol. Sci., 113 (3), 203-207.
146. Wang, X., Lee, S.R., Arai, K., Tsuji, K., Rebeck, G.W., and Lo, E.H. (2003) Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med., 9 (10), 1313-1317.
147. Yepes, M., Sandkvist, M., Moore, E.G., Bugge, T.H., Strickland, D.K., and Lawrence, D.A. (2003) Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest., 112 (10), 1533-1540.
148. Lee, S.R., Guo, S.Z., Scannevin, R.H., Magliaro, B.C., Rhodes, K.J., Wang, X., and Lo, E.H. (2007) Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci. Lett., 417 (1), 1-5.
149. Tsuji, K., Aoki, T., Tejima, E., Arai, K., Lee, S.R., Atochin, D.N., Huang, P.L., Wang, X., Montaner, J., and Lo, E.H. (2005) Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke, 36 (9), 1954-1959.
150. Aoki, T., Sumii, T., Mori, T., Wang, X., and Lo, E.H. (2002) Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke, 33 (11), 2711-2717.
151. Kelly, M.A., Shuaib, A., and Todd, K.G. (2006) Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp. Neurol., 200 (1), 38-49.
152. Del Zoppo, G.J. (2010) The neurovascular unit, matrix proteases, and innate inflammation. Ann. N.Y. Acad. Sci., 1207, 46-49.
153. Copin, J.C., Bengualid, D.J., Da Silva, R.F., Kargiotis, O., Schaller, K., and Gasche, Y. (2011) Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse. Eur. J. Neurosci., 34 (7), 1085-1092.
154. Gidday, J.M., Gasche, Y.G., Copin, J.C., Shah, A.R., Perez, R.S., Shapiro, S.D., Chan, P.H., and Park, T.S. (2005) Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol., 289 (2), H558-H568.
155. Justicia, C., Panes, J., Sole, S., Cervera, A., Deulofeu, R., Chamorro, A., and Planas, A.M. (2003) Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J. Cereb. Blood Flow Metab., 23 (12), 1430-1440.
156. Harris, A.K., Ergul, A., Kozak, A., Machado, L.S., Johnson, M.H., and Fagan, S.C. (2005) Effect of neutrophil depletion on gelatinase expression, edema formation and hemorrhagic transformation after focal ischemic stroke. BMC Neurosci., 6, 49.
157. Cuadrado, E., Ortega, L., Hernandez-Guillamon, M., Penalba, A., Fernandez-Cadenas, I., Rosell, A., and Montaner, J. (2008) Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J. Leukoc. Biol., 84 (1), 207-214.
158. Rosell, A., Ortega-Aznar, A., Alvarez-Sabin, J., Fernandez-Cadenas, I., Ribo, M., Molina, C.A., Lo, E.H., and Montaner, J. (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke, 37 (6), 1399-1406.
159. Herz, J. and Strickland, D.K. (2001) LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest., 108 (6), 779-784.
160. Lillis, A.P., Van Duyn, L.B., Murphy-Ullrich, J.E., and Strickland, D.K. (2008) LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev., 88 (3), 887-918.
161. Biessen, E.A., van Teijlingen, M., Vietsch, H., Barrett-Bergshoeff, M.M., Bijsterbosch, M.K., Rijken, D.C., van Berkel, T.J., and Kuiper, J. (1997) Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator. Circulation, 95 (1), 46-52.
162. Lillis, A.P., Mikhailenko, I., and Strickland, D.K. (2005) Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J. Thromb. Haemost., 3 (8), 1884-1893.
163. Bu, G., Williams, S., Strickland, D.K., and Schwartz, A.L. (1992) Low density lipoprotein receptor-related protein/ alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc. Natl. Acad. Sci. U.S.A., 89 (16), 7427-7431.
164. Makarova, A., Mikhailenko, I., Bugge, T.H., List, K., Lawrence, D.A., and Strickland, D.K. (2003) The low density lipoprotein receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin-tissue-type plasminogen activator complexes. J. Biol. Chem., 278 (50), 50250-50258.
165. May, P., Reddy, Y.K., and Herz, J. (2002) Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J. Biol. Chem., 277 (21), 18736-18743.
166. Su, E.J., Fredriksson, L., Geyer, M., Folestad, E., Cale, J., Andrae, J., Gao, Y., Pietras, K., Mann, K., Yepes, M., Strickland, D.K., Betsholtz, C., Eriksson, U., and Lawrence, D.A. (2008) Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med., 14 (7), 731-737.
167. Polavarapu, R., Gongora, M.C., Yi, H., Ranganthan, S., Lawrence, D.A., Strickland, D., and Yepes, M. (2007) Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood, 109 (8), 3270-3278.
168. Zhang, X., Polavarapu, R., She, H., Mao, Z., and Yepes, M. (2007) Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein mediate cerebral ischemia-induced nuclear factor-?B pathway activation. Am. J. Pathol., 171 (4), 1281-1290.
169. Fredriksson, L., Li, H., and Eriksson, U. (2004) The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev., 15 (4), 197-204.
170. Fredriksson, L., Li, H., Fieber, C., Li, X., and Eriksson, U. (2004) Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J., 23 (19), 3793-3802.
171. Su, E.J., Fredriksson, L., Schielke, G.P., Eriksson, U., and Lawrence, D.A. (2009) Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J. Thromb. Haemost., 7 (Suppl. 1), 155-158.
172. Tang, Z., Arjunan, P., Lee, C., Li, Y., Kumar, A., Hou, X., Wang, B., Wardega, P., Zhang, F., Dong, L., Zhang, Y., Zhang, S.Z., Ding, H., Fariss, R.N., Becker, K.G., Lennartsson, J., Nagai, N., Cao, Y., and Li, X. (2010) Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation. J. Exp. Med., 207 (4), 867-880.
173. Fredriksson, L., Nilsson, I., Su, E.J., Andrea, J., Ding, H., Betsholtz, C., Eriksson, U., and Lawrence, D.A. (2012) Platelet-derived growth factor C deficiency in C57BL/6 mice leads to abnormal cerebral vascularization, loss of neuroependymal integrity, and ventricular abnormalities. Am. J. Pathol, http://dx.doi.org/10.1016/j.ajpath.2011.12.006
174. Andrae, J., Gallini, R., and Betsholtz, C. (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev., 22 (10), 1276-1312.
175. He, Y., Cai, W., Wang, L., and Chen, P. (2009) A developmental study on the expression of PDGFalphaR immunoreactive cells in the brain of postnatal rats. Neurosci. Res., 65 (3), 272-279.
176. Jackson, E.L., Garcia-Verdugo, J.M., Gil-Perotin, S., Roy, M., Quinones- Hinojosa, A., VandenBerg, S., and Alvarez-Buylla, A. (2006) PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron, 51 (2), 187-199.
177. Pringle, N.P., Mudhar, H.S., Collarini, E.J., and Richardson, W.D. (1992) PDGF receptors in the rat CNS: during late neurogenesis, PDGF alpha-receptor expression appears to be restricted to glial cells of the oligodendrocyte lineage. Development, 115 (2), 535-551.
178. Chang, C., Wang, X., and Caldwell, R.B. (1997) Serum opens tight junctions and reduces ZO-1 protein in retinal epithelial cells. J. Neurochem., 69 (2), 859-867.
179. Ivens, S., Gabriel, S., Greenberg, G., Friedman, A., and Shelef, I. (2010) Blood-brain barrier breakdown as a novel mechanism underlying cerebral hyperperfusion syndrome. J. Neurol., 257 (4), 615-620.
180. Ma, Q., Huang, B., Khatibi, N., Rolland, W.II., Suzuki, H., Zhang, J.H., and Tang, J. (2011) PDGFR-a inhibition preserves blood-brain barrier after intracerebral hemorrhage. Ann. Neurol, 70, 920-931.